Biogen @biogen

Official global newsroom account for Biogen, a leading biotech company pioneering innovative science since 1978. Community guidelines: https://t.co/56frPQHf74 biogen.com Cambridge, MA Joined June 2010

Tweets

6K
Followers

45K
Following

240
Likes

1K

Biogen @biogen

2 days ago

Join us at #WMS2026 for our symposium where leading experts will discuss ongoing research in spinal muscular atrophy (SMA) and practical considerations for optimizing care for people living with SMA.

1 0 0 614 0

View Details

Biogen @biogen

4 days ago

At #TTS2026 we're presenting key insights into antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Join our symposium and stop by booth #15 and #16 to learn about Biogen's work in these complicated and burdensome forms of kidney disease.

1 2 2 841 1

View Details

Biogen @biogen

a week ago

#News: Today, the Clinical Journal of the American Society of Nephrology published results from a Phase 3 analysis in adolescents with C3G and primary IC-MPGN. Read more: bit.ly/476pxiU

1 1 3 987 0

View Details

Biogen @biogen

2 weeks ago

We’re heading to New Orleans for #PsychCongress2026! Together with Supernus Pharmaceuticals, we’ll share the latest real-world evidence in postpartum depression (PPD). Attending? Connect with our team and visit us at booth 1041. Learn more: spr.ly/6016BGHj4y

0 1 2 910 0

View Details

Biogen @biogen

3 weeks ago

At #EEC2026 we’re sharing the latest data from our investigational study for Dravet syndrome, exploring the disease’s underlying genetic cause. Stop by booth #38 and join us at our medical symposium to learn more about our work in this genetic and highly burdensome disease.

1 2 6 792 0

View Details

Biogen @biogen

3 weeks ago

#News: With @StokeTx we’re presenting data on an investigational drug for Dravet syndrome at #EEC2026. Read more about these data: bit.ly/4cvvnO1

0 2 4 891 0

View Details

Biogen @biogen

3 weeks ago

#News: We are attending #EEC2026 alongside @StokeTx to share our latest findings in Dravet syndrome. Read more about our upcoming presentations: bit.ly/4zMJicq

0 0 3 871 0

View Details

Biogen @biogen

2 months ago

#News: We announced the completion of the acquisition of RayThera Inc. This acquisition marks another step in growing Biogen’s immunology portfolio, adding multiple potential assets for immune-mediated diseases. Read more: spr.ly/6012B1Dlmq

3 3 9 2K 0

View Details

Biogen @biogen

2 months ago

We’re attending #GlomConHawaii to share more about our approach to C3G and primary IC-MPGN. Stop by booth #25 to learn how Biogen is working to transform care in complement-driven and immune-mediated kidney diseases.

1 0 4 1K 0

View Details

Biogen @biogen

2 months ago

STARTING SOON: Join our Q2 2026 earnings call webcast at 8:30AM ET here: spr.ly/6015BEIIcd #Earnings $BIIB

1 0 2 805 0

View Details

Biogen @biogen

2 months ago

Today, we reported our Q2 results, demonstrating progress toward our goal of sustainable revenue growth. Read more: bit.ly/4yNFlUk Forward-looking statements: biogen.com/forward-lookin… #Earnings $BIIB

0 0 2 934 0

View Details

Biogen @biogen

2 months ago

#News: Today @synapticure announced its new ataxia care program. We’re proud to help support important awareness efforts as a part of our commitment to the broader ataxia communities. Read more: bit.ly/4vwPwtC

0 3 7 1K 0

View Details

Biogen @biogen

2 months ago

Our team will be at the @asrsdocs Annual Meeting to share 7 research abstracts that highlight our understanding of geographic atrophy (GA), a leading cause of blindness. Stop by Booth #1101 to learn more about our work in GA.

0 3 4 1K 0

View Details

Biogen @biogen

2 months ago

#News: Together with Eisai, we announced that the FDA has approved a new delivery option for people living with early Alzheimer’s disease. Learn more: bit.ly/4wGKCeL

0 1 8 1K 0

View Details

Biogen @biogen

3 months ago

#News: We’re attending the @alzassociation’s International Conference (#AAIC26) to share new data from our Alzheimer’s disease portfolio—including initial data from the Phase 2 study of our investigational tau-targeting therapy. Learn more: bit.ly/4eyKc3U

0 1 9 2K 2

View Details

Biogen @biogen

3 months ago

We’re in San Diego this week at #BIO2026 and look forward to connecting with biotech leaders from across the globe who share our ambition to deliver medicines to help transform patients’ lives. Learn about our partnering opportunities around the world: bit.ly/4gudEJC

1 2 4 1K 0

View Details

Biogen @biogen

3 months ago

At the @ATCMeeting, we're sharing new data on our investigational therapy designed to target CD-38 cells in antibody-mediated rejection. Join us to learn about our ongoing research in kidney transplantation and our late-stage clinical trials. Learn more: ow.ly/MNtN50ZcR2t

1 1 4 631 0

View Details

Biogen @biogen

3 months ago

#News: Today, we announced an agreement to acquire RayThera Inc. With this deal, we aim to add multiple immunology assets to our portfolio that will contribute to our long-term pipeline potential. Read more about this deal: ow.ly/ogXF50Ze1H3

1 4 9 1K 0

View Details

Biogen @biogen

4 months ago

#News: Today, we announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for an investigational therapy for spinal muscular atrophy (SMA). Learn more about this important milestone: bit.ly/49B9vj0

1 4 16 1K 1

View Details

Biogen @biogen

4 months ago

#News: With @ucb_news, we announced data at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, for an investigational therapy for systemic lupus erythematosus (SLE). Learn more about the data: bit.ly/4uTeELQ